Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
暂无分享,去创建一个
William F. Fadel | S. E. Reese | C. Mcevoy | R. Link-Gelles | P. Embí | K. Natarajan | S. Grannis | B. Fireman | A. Naleway | M. Gaglani | M. Thompson | Toan C Ong | Patrick K. Mitchell | K. Murthy | B. Dixon | N. Klein | Stephanie A. Irving | M. DeSilva | N. Lewis | L. Blanton | J. Ferdinands | R. Birch | E. Stenehjem | Eric P. Griggs | K. Goddard | O. Zerbo | W. Fadel | K. Dascomb | Catherine H Bozio | M. Barron | Jungmi Han | Chandni Raiyani | Kristin Goddard | Jeremiah Williams | E. Griggs | Monica Dickerson | S. Rao | P. Patel | I-Chia Liao | N. Grisel | Duck-Hye Yang | Julie Arndorfer | S. Irving | J. Arndorfer | C. Raiyani | N. Valvi | M. Dickerson | Ousseny Zerbo | Nimish Valvi | Kempapura Murthy
[1] S. Ethelberg,et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study , 2022, PLoS medicine.
[2] Sarah E. Wilson,et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study , 2022, BMJ.
[3] L. Abu-Raddad,et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization , 2022, Vaccine.
[4] S. Ethelberg,et al. Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study , 2022, medRxiv.
[5] H. Bregman,et al. Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[6] M. Exline,et al. mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients , 2022, The Journal of infectious diseases.
[7] J. Starrfelt,et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021 , 2022, BMC Medicine.
[8] T. Pavlík,et al. Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2 , 2022, medRxiv.
[9] William F. Fadel,et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[10] O. A. Ogun,et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.
[11] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[12] D. Montefiori,et al. Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.
[13] William F. Fadel,et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[14] N. Andrews,et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines , 2022, The New England journal of medicine.
[15] Y. Kreiss,et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.
[16] J. Starrfelt,et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January to September 2021. , 2021, medRxiv.
[17] William F. Fadel,et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[18] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.
[19] A. Harries,et al. Faculty Opinions recommendation of Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[20] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[21] K. Bruxvoort,et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study , 2021, BMJ.
[22] D. Montefiori,et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis , 2021, Nature Medicine.
[23] S. Schrag,et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings , 2021, The New England journal of medicine.
[24] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[25] D. Cummings,et al. Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness , 2021, medRxiv.
[26] K. Schulman,et al. Beyond Politics - Promoting Covid-19 Vaccination in the United States. , 2021, The New England journal of medicine.
[27] A. Nordström,et al. Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study , 2021, SSRN Electronic Journal.
[28] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[29] M. Lipsitch,et al. Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.
[30] John Adams. Assessing , 2020, Transport Planning.
[31] Thomas E Novotny,et al. US Department of Health and Human Services: a need for global health leadership in preparedness and health diplomacy. , 2006, American journal of public health.
[32] S Greenland,et al. Maximum likelihood estimation of the attributable fraction from logistic models. , 1993, Biometrics.